跳至主要内容
临床试验/NL-OMON27982
NL-OMON27982招募中不适用

A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinoma.

ot applicable0 个研究点目标入组 43 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
ot applicable
入组人数
43

研究概览

简要总结

/A

研究设计

研究类型
Interventional

入排标准

入选标准

  • Histologically proven, irresectable gastric adenocarcinoma, except carcinoma of the cardia, WHO 0-2, ability to swallow, adequate hepatic, renal and bone marrow function.

排除标准

  • Prior chemotherapy or radiotherapy, current treatment with HMG-CoA-reductase inhibitor, peripheral neurotoxicity grade >2.

研究者

发起方
ot applicable

相似试验

已完成
不适用
A randomized phase II trial comparing epirubicin, cisplatin, and capecitabine versus the combination of epirubicin, cisplatin, and capecitabine with pravastatin in patients with irresectable or metastatic gastric carcinomaCancer
ISRCTN23062732Erasmus Medical Center, Department of Medical Oncology (Netherlands)43
招募中
不适用
Phase II randomized controlled trial of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinomahepatocellular carcinoma
JPRN-UMIN000011785Takasaki General Medical Center, National Hospital Organization60
进行中(未招募)
1 期
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine and Herceptin in Early Breast Cancerearly HER-2 breast cancer
EUCTR2004-002030-19-ATAUSTRIAN BREAST CANCER STUDY GROUP536
进行中(未招募)
1 期
A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial - ELECT trialAdvanced Gastro-oesophageal cancerMedDRA version: 9.1Level: LLTClassification code 10062878Term: Gastrooesophageal cancer
EUCTR2006-003332-29-GBICORG, all-Ireland Cooperative Oncology Research Group140
进行中(未招募)
不适用
A Randomised Phase II trial of Epirubicin, Oxaliplatin and Capecitebine (EOX) versus Docetaxel and Oxaliplatin (EITax) in the treatment of Advanced Gastro-oesophageal cancer - The ELECT trial - ELECT trialAdvanced Gastro-oesophageal cancerMedDRA version: 9.1Level: LLTClassification code 10062878Term: Gastrooesophageal cancer
EUCTR2006-003332-29-IEICORG, all-Ireland Cooperative Oncology Research Group140
A randomized phase II trial comparing epirubicin,... | 临床试验